HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 9, Issue 9, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-11
DOI
10.1038/s41419-018-0931-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EGF-stimulated activation of Rab35 regulates RUSC2–GIT2 complex formation to stabilize GIT2 during directional lung cancer cell migration
- (2016) Biao Duan et al. CANCER LETTERS
- New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
- (2016) Sherry X. Yang et al. CANCER TREATMENT REVIEWS
- Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma
- (2016) Matthew H. Wong et al. NEOPLASIA
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition
- (2015) Z Meng et al. ONCOGENE
- HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer
- (2014) Se Jin Park et al. CANCER LETTERS
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
- (2014) Ozgur Sahin et al. CELL RESEARCH
- HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
- (2014) Si-Meng Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
- (2014) Jinwon Seo et al. Journal of Breast Cancer
- Drugging the HDAC6–HSP90 interplay in malignant cells
- (2014) Oliver H. Krämer et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth
- (2013) S. A. Gradilone et al. CANCER RESEARCH
- PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer
- (2013) Giovanni Luca Gravina et al. ENDOCRINE-RELATED CANCER
- Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
- (2013) Sabina Berezowska et al. PLoS One
- Microtubules Coordinate VEGFR2 Signaling and Sorting
- (2013) Catherine Czeisler et al. PLoS One
- Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
- (2013) M. J. Niederst et al. Science Signaling
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation
- (2011) Yisheng Jiao et al. Molecular Cancer
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop
- (2011) M. Keniry et al. Cancer Discovery
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- The Role of HDAC6 in Cancer
- (2010) Grace I. Aldana-Masangkay et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90
- (2010) Qingwei Meng et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
- (2009) P Cao et al. BRITISH JOURNAL OF CANCER
- Targeted therapy of metastatic breast cancer
- (2009) Alfonso Sánchez-Muñoz et al. Clinical & Translational Oncology
- The upgraded role of HER3 and HER4 receptors in breast cancer
- (2009) Angelos K. Koutras et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel
- (2008) A. Sawai et al. CANCER RESEARCH
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Destabilization of ERBB2 Transcripts by Targeting 3' Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6
- (2008) G. K. Scott et al. MOLECULAR CANCER RESEARCH
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- Beyond tamoxifen: Extended and late extended endocrine therapy in postmenopausal early breast cancer
- (2007) David Dodwell et al. CANCER TREATMENT REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started